Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Braz. j. med. biol. res ; 47(5): 384-393, 02/05/2014. tab, graf
Article in English | LILACS | ID: lil-709441

ABSTRACT

Recognition of pathogens is performed by specific receptors in cells of the innate immune system, which may undergo modulation during the continuum of clinical manifestations of sepsis. Monocytes and neutrophils play a key role in host defense by sensing and destroying microorganisms. This study aimed to evaluate the expression of CD14 receptors on monocytes; CD66b and CXCR2 receptors on neutrophils; and TLR2, TLR4, TLR5, TLR9, and CD11b receptors on both cell types of septic patients. Seventy-seven septic patients (SP) and 40 healthy volunteers (HV) were included in the study, and blood samples were collected on day zero (D0) and after 7 days of therapy (D7). Evaluation of the cellular receptors was carried out by flow cytometry. Expression of CD14 on monocytes and of CD11b and CXCR2 on neutrophils from SP was lower than that from HV. Conversely, expression of TLR5 on monocytes and neutrophils was higher in SP compared with HV. Expression of TLR2 on the surface of neutrophils and that of TLR5 on monocytes and neutrophils of SP was lower at D7 than at D0. In addition, SP who survived showed reduced expression of TLR2 and TLR4 on the surface of neutrophils at D7 compared to D0. Expression of CXCR2 for surviving patients was higher at follow-up compared to baseline. We conclude that expression of recognition and cell signaling receptors is differentially regulated between SP and HV depending on the receptor being evaluated.


Subject(s)
Adult , Aged , Child, Preschool , Female , Humans , Male , Middle Aged , Chemokines/blood , Integrins/blood , Monocytes/chemistry , Neutrophils/chemistry , Sepsis/immunology , Toll-Like Receptors/blood , Anti-Bacterial Agents/therapeutic use , Antigens, CD/blood , /blood , /blood , Cell Adhesion Molecules/blood , Flow Cytometry , GPI-Linked Proteins/blood , Hospital Mortality , Immunophenotyping , Intensive Care Units , /blood , Statistics, Nonparametric , Sepsis/therapy , Treatment Outcome , Toll-Like Receptor 9/blood , /blood , /blood , /blood
2.
Braz. j. med. biol. res ; 39(10): 1339-1347, Oct. 2006. tab
Article in English | LILACS | ID: lil-437818

ABSTRACT

The objective of the present study was to assess the incidence, risk factors and outcome of patients who develop acute renal failure (ARF) in intensive care units. In this prospective observational study, 221 patients with a 48-h minimum stay, 18-year-old minimum age and absence of overt acute or chronic renal failure were included. Exclusion criteria were organ donors and renal transplantation patients. ARF was defined as a creatinine level above 1.5 mg/dL. Statistics were performed using Pearsons' chi2 test, Student t-test, and Wilcoxon test. Multivariate analysis was run using all variables with P < 0.1 in the univariate analysis. ARF developed in 19.0 percent of the patients, with 76.19 percent resulting in death. Main risk factors (univariate analysis) were: higher intra-operative hydration and bleeding, higher death risk by APACHE II score, logist organ dysfunction system on the first day, mechanical ventilation, shock due to systemic inflammatory response syndrome (SIRS)/sepsis, noradrenaline use, and plasma creatinine and urea levels on admission. Heart rate on admission (OR = 1.023 (1.002-1.044)), male gender (OR = 4.275 (1.340-13642)), shock due to SIRS/sepsis (OR = 8.590 (2.710-27.229)), higher intra-operative hydration (OR = 1.002 (1.000-1004)), and plasma urea on admission (OR = 1.012 (0.980-1044)) remained significant (multivariate analysis). The mortality risk factors (univariate analysis) were shock due to SIRS/sepsis, mechanical ventilation, blood stream infection, potassium and bicarbonate levels. Only potassium levels remained significant (P = 0.037). In conclusion, ARF has a high incidence, morbidity and mortality when it occurs in intensive care unit. There is a very close association with hemodynamic status and multiple organ dysfunction.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged, 80 and over , Acute Kidney Injury , Hospital Mortality , Intensive Care Units/statistics & numerical data , Acute Kidney Injury , Analysis of Variance , APACHE , Creatine/blood , Incidence , Length of Stay , Prognosis , Prospective Studies , Risk Factors , Treatment Outcome
3.
Braz. j. med. biol. res ; 39(1): 107-117, Jan. 2006. tab, graf
Article in English | LILACS | ID: lil-419152

ABSTRACT

The objective of the present study was to evaluate the duodenal mucosa of HIV-infected patients during antiretroviral therapy. This was an observational study conducted on HIV-positive patients and a control group. Group 1 comprised 22 HIV-negative individuals while 38 HIV-positive individuals were classified according to the CDC 1993 classification into group 2 (A1 or A2) or group 3 (B2, A3, B3, C2, C3). All subjects were submitted to upper gastrointestinal endoscopy with duodenal biopsies. Qualitative, semi-quantitative and quantitative histological analyses were performed. Results were considered significant when P < 0.05. A higher prevalence of inflammatory infiltrate and eosinophilia was observed in the HIV group, together with a reduction in mucosal CD4+ lymphocyte (L) counts [median (lower-upper quartiles), 12.82 (8.30-20.33), 6.36 (1.75-11.66) and 1.75 (0.87-3.14) in groups 1, 2 and 3, respectively] which was not correlated with disease stage. The extent of CD4+L count reduction was similar in blood and duodenal mucosa. Normal CD8+L and CD45RO+L counts, and normal numbers of macrophages and antigen-presenting cells were also found in the HIV patients. The cytokine pattern did not differ among groups. Tissue HIV, assessed by p24 antigen, correlated with a higher CD45RO+L count (77.0 (61-79.8) and 43.6 (31.7-62.8) in p24+ and p24-, respectively, P = 0.003), and IL-4 positivity (100 and 48.2 percent in p24+ and p24-, respectively, P = 0.005). The duodenal mucosa of HIV+ patients showed a relatively preserved histological architecture. This finding may be characteristic of a population without opportunistic infections and treated with potent antiretroviral therapy, with a better preservation of the immune status.


Subject(s)
Humans , Male , Female , Antiretroviral Therapy, Highly Active , Anti-HIV Agents/therapeutic use , Duodenum/immunology , HIV Infections/drug therapy , Intestinal Mucosa/immunology , Reverse Transcriptase Inhibitors/therapeutic use , Case-Control Studies , /immunology , Duodenoscopy , Duodenum/pathology , HIV Infections/immunology , HIV Infections/pathology , Intestinal Mucosa/pathology , Viral Load
4.
Rev. Soc. Bras. Med. Trop ; 31(2): 221-224, mar.-abr. 1998. ilus
Article in Portuguese | LILACS | ID: lil-464103

ABSTRACT

Os autores relatam um caso de leishmaniose cutâneo-mucosa em uma paciente de 89 anos, diabética e hipertensa, tratada inicialmente com alopurinol por 10 meses não havendo cicatrização das lesões. Posteriormente, recebeu antimoniato de N-metil glucamina (glucantime) por 4 dias, na dose total de 2.380mg do Sbv, mas desenvolveu cardiotoxicidade e hipocalemia, sendo suspenso o tratamento, entretanto, evoluiu com regressão clínica total das lesões, apesar de ter recebido pequena dose desta medicação.


The authors report a case of a 89 years-old woman with mucocutaneous leishmaniasis and previous diabetes mellitus and high blood pressure, who had been treated with allopurinol for 10 months without healing of lesions. Afterwards, she has been treated with meglumine antimonate, [quot ]glucantime[quot ] for 4 days, with a total dose 2,380 mg of Sbv, but developed cardiac side effects and hypokalemia, hence the treatment was withdrawn. However, this patient developed total clinical regression of lesions, in spite of she has been received low dose of this drug.


Subject(s)
Aged , Aged, 80 and over , Female , Humans , Antiprotozoal Agents/administration & dosage , Organometallic Compounds/administration & dosage , Facial Dermatoses/drug therapy , Leishmaniasis, Mucocutaneous/drug therapy , Meglumine/administration & dosage , Facial Dermatoses/blood , Facial Dermatoses/parasitology , Leishmaniasis, Mucocutaneous/blood
SELECTION OF CITATIONS
SEARCH DETAIL